Ketamine for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
Obsessive-Compulsive Disorder+1 More
Ketamine - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will test how well ketamine works to reduce OCD symptoms compared to a placebo.

Eligible Conditions
  • Obsessive-Compulsive Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obsessive-Compulsive Disorder

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 6 months

Up to 6 months
improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)
up to 90 minutes
Regional gamma-aminobutyric acid, glutamate/glutamine levels derived from 3T Magnetic Resonance Spectroscopy

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Obsessive-Compulsive Disorder

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control
Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: Ketamine · No Placebo Group · Phase 2

Experimental Group · 1 Intervention: Ketamine · Intervention Types: Drug
ActiveComparator Group · 1 Intervention: Midazolam · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,148 Previous Clinical Trials
35,679,048 Total Patients Enrolled
10 Trials studying Obsessive-Compulsive Disorder
720 Patients Enrolled for Obsessive-Compulsive Disorder
University of ConnecticutOTHER
159 Previous Clinical Trials
156,136 Total Patients Enrolled
Carolyn I Rodriguez, MD, PhDPrincipal InvestigatorStanford University
3 Previous Clinical Trials
41 Total Patients Enrolled
1 Trials studying Obsessive-Compulsive Disorder
7 Patients Enrolled for Obsessive-Compulsive Disorder

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a primary diagnosis of OCD.
You have the capacity to give informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 17th, 2021

Last Reviewed: October 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
Stanford University100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria33.3%
Met criteria66.7%

How responsive is this trial?

Most responsive sites:
  1. Stanford University: < 24 hours
Typically responds via
Average response time
  • < 1 Day